Efficacy, Safety and Predictors of Response to Rituximab in Treatment of Iraqi Patients with Active Rheumatoid Arthritis
Al- Anbar Medical Journal,
2019, Volume 15, Issue 1, Pages 16-21
Abstract
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody which effectively depletes B cells and is used for treating rheumatoid arthritis (RA). Objectives: To assess the efficacy and safety of RTX and to evaluate the predictors of response to RTX in the treatment of Iraqi patients with active RA. Materials and methods: An open-labeled single group study that was conducted over 13 months in 65 patients with RA diagnosed according to a 1987 American College of Rheumatology (ACR) criteria. All patients were given 4 doses RTX by intravenous infusion over 6 months 1gm/dose. Each patient was followed at each visit of disease activity, including the Clinical Disease Activity Index (CDAI) and functional class (F Class). Also, we assess 9 different patients’ characteristics (age, gender, disease duration, the presence of RF, presence of ACPA, smoking status, previous use of TNF-blocker, the use of methotrexate and BMI) as predictors to RTX. Results: Data analysis showed significant improvement in CDAI (P value=0.005) and functional disability (P-value =0.001), and ESR (P-value =0.005) with RTX use over 6 months. The analysis also showed that smoking has a negative correlation with response to treatment (p-value = 0.005). A better response was seen in RF-positive group. The other variables had no effects on the response to treatment. The patients who switched from TNF-blocker were (29), and the patients who started on RTX were 36 (either due to positive Purified Protein Derivative of a tuberculin test (PPD) or unavailability of TNF-blocker), results showed same RTX efficacy in both groups. Conclusion: RTX is effective both clinically (CDAI and F Class) and laboratory (ESR). It is more effective in patients who are not smokers, and in those who are seropositive for RF. RTX is relatively safe with few side effects, tolerable by most patients. The most common side effect is a transfusion reaction in the form of a sore throat.A. Silman et al. Proposal to establish a register for the
long term surveillance of adverse events in patients with
rheumatic diseases exposed to biological agents: the eu-
lar surveillance register for biological compound.Ann.
Rheum. Dis., 59(6):419–420, 2000.
[2] J. B. Imboden, D. B. Hellmann, and J. H. Stone. Current
diagnosis and treatment in rheumatology.McGraw Hill
Professional, 2013.
[3] GS Firestein, RC Budd, and SE Gabriel et al. RA etiol-
ogy and pathogenesis. in: Gary s. f.Kelleys Textbook of
Rheumatology. 9thEd. China, Elsevier, page 1059, 2013.
[4] M., SH. Ralstom, and BR. Walker et al. Musculoskele-
tal disorders. In.Davidsons Principles and Practice of
Medicine. 21thEd. London:Elseviers Health Sciences
Rights Departmen, page 1088, 2010.
[5] ZS. Al-Rawi,AJ. Alazzawi,and FM. Al-Ajilli et al.
Rheumatoid arthritis in population samples in iraq.Ann
Rheum Dis, 37(1):73–75, 1978.
[6] TH Al-Saadawi. The association of smoking with disease
activity and appearance of extra- articular manifestation
in RA patients.Post– Grad. Med. J., 12(1):146–152,
2013.
[7] SE. Sweney, ED Harris, and GS. Firestein et al.Clini-
cal features of rheumatoid arthritis.Kelleys Textbook of
Rheumatology. 9thEd. China, Elsevier, pages 1109–1136,
2013.
[8] D.Aletahaetal.2010rheumatoidarthritisclassi-
ficationcriteria:anamericancollegeofrheumatol-
ogy/european league against rheumatism collaborative
initiative.Arthritis Rheum., 62(9):2569–2581, 2010.
[9] N. A. Jassim and DH Ibrahim. Efficacy, safety and pre-
dictors of response to etanercept in treatment of iraqi
patients with active RA.Diploma thesis, University of
Baghdad, College of Medicine, Rheumatology Unit, 2013.
[10] A. Sonya, B. Andrew, and D. Michoel et al. Arthritis. in:
Margaret c.Rheumatology Handbook .London: Imperial
College, Press, pages 104–107, 2012.
[11] J. S. Smolen et al.EULAR recommendations for the
management of rheumatoid arthritis with synthetic and
biological disease-modifying antirheumatic drugs.Ann.
Rheum. Dis., 69(6):964–975, 2010.
[12] C.J. Mary et al. Recommendations for the use of ritux-
imab in anti-neutrophil cytoplasm antibody-associated
vasculitis.Rheumatology, 51(4):634–643, 2011.
[13] B. M. Alexandre, J. L. Jissa, and D. S. Marcelo et al.
Rituximab pharmacology,clinical uses and health ef-
fects.pharmacology and clinical applications, pages 31–
46, 2012.
[14] A.A.SchunaandS.William.Rituximabforthe
treatment of rheumatoid arthritis.Pharmacotherapy,
27(12):1702–1710, 2007.
[15] Q. Luca, S. Sara, and F. Martina et al. Cost saving and
predictive factors of response to RTX in RA.Salvatore
De Vita, Clinic of Rheumatology, University Hospital of
Udine, Piazzale S. Maria della Misericordia, 15(4):8696–
1 – 8696–8, 2012
Rituximab in Treatment of Active RAANB. MED. J. 15(1), 2019
[16] C. W. Jonathan et al. Efficacy of b-celltargeted therapy
with rituximab in patients with rheumatoid arthritis.N.
Engl. J. Med., 350(25):2572–2581, 2004.
[17] A. Richter et al. Sustainability of rituximab therapy in
different treatment strategies: Results of a 3year follow-
up of a german biologics register.Arthritis Care Res.
(Hoboken), 66(11):1627–1633, 2014.
[18] R. F. van Vollenhoven, R. M. Fleischmann, D. E. Furst,
S. Lacey, and P. B. Lehane.Longterm safety of ritux-
imab: final report of rheumatoid arthritis global clinical
trial program over 11 years.J. Rheumatol, 42(10):1761–
1766, 2015.
[19] A. Khan, D. L. Scott, and M. Batley. Smoking, rheuma-
toid factor status and responses to rituximab.Ann.
Rheum. Dis., 71(9):1587–1588, 2012.
[20] M.A. Lopez-Olivo et al.Rituximab for rheumatoid arthri-
tis.Cochrane Database Syst. Rev., 2017(6):99–111, 2015.
[21] J. D. Isaacs et al.Effect of baseline rheumatoid factor
and anticitrullinated peptide antibody serotype on rit-
uximab clinical response: a meta-analysis.Ann. Rheum.
Dis., 72(3):329–336, 2013.
[22] J. Wendler et al. Rituximab in patients with rheumatoid
arthritis in routine practice (GERINIS): six-year results
from a prospective, multicentre, non-interventional study
in 2,484 patients.Arthritis Res. Ther., 16(2):R80, 2014.
[23] J. Sellam et al.B cell activation biomarkers as predic-
tive factors for the response to rituximab in rheumatoid
arthritis:a sixmonth, national, multicenter, openlabel
study.Arthritis Rheum., 63(4):933–938, 2011.
[24] R. van Vollenhoven et al. long-term safety of rituximab:
Pooled analysis of the rheumatoid arthritis global clinical
trial program over 11 years.:2342.Arthritis Rheum.,
65:S1000, 2013.
[25] D. Ennishi et al. Does rituximab really induce hepatitis
c virus reactivation?J. Clin. Oncol., 26(28):4695–4696,
2008
- Article View: 15
- PDF Download: 9